Inovio Pharmaceuticals Inc (NASDAQ: INO) kicked off on Monday, down -7.07% from the previous trading day, before settling in for the closing price of $1.98. Over the past 52 weeks, INO has traded in a range of $1.74-$14.75.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 97.63% over the past five years. While this was happening, its average annual earnings per share was recorded 30.90%. With a float of $35.88 million, this company’s outstanding shares have now reached $36.10 million.
Let’s look at the performance matrix of the company that is accounted for 122 employees. In terms of profitability, gross margin is -767.0%, operating margin of -58709.67%, and the pretax margin is -12414736.82%.
Inovio Pharmaceuticals Inc (INO) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Inovio Pharmaceuticals Inc is 0.61%, while institutional ownership is 37.08%.
Inovio Pharmaceuticals Inc (INO) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 30.90% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 29.92% during the next five years compared to 13.49% growth over the previous five years of trading.
Inovio Pharmaceuticals Inc (NASDAQ: INO) Trading Performance Indicators
Take a look at Inovio Pharmaceuticals Inc’s (INO) current performance indicators. Last quarter, stock had a quick ratio of 3.88. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 332.13.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.48, a number that is poised to hit -0.84 in the next quarter and is forecasted to reach -2.92 in one year’s time.
Technical Analysis of Inovio Pharmaceuticals Inc (INO)
Inovio Pharmaceuticals Inc (NASDAQ: INO) saw its 5-day average volume 0.58 million, a negative change from its year-to-date volume of 0.93 million. As of the previous 9 days, the stock’s Stochastic %D was 18.33%. Additionally, its Average True Range was 0.16.
During the past 100 days, Inovio Pharmaceuticals Inc’s (INO) raw stochastic average was set at 2.44%, which indicates a significant decrease from 3.92% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 74.71% in the past 14 days, which was lower than the 101.53% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.0093, while its 200-day Moving Average is $6.0426. Nevertheless, the first resistance level for the watch stands at $1.9467 in the near term. At $2.0533, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.1067. If the price goes on to break the first support level at $1.7867, it is likely to go to the next support level at $1.7333. Assuming the price breaks the second support level, the third support level stands at $1.6267.
Inovio Pharmaceuticals Inc (NASDAQ: INO) Key Stats
The company with the Market Capitalisation of 66.43 million has total of 26,100K Shares Outstanding. Its annual sales at the moment are 830 K in contrast with the sum of -135,120 K annual income. Company’s last quarter sales were recorded 100 K and last quarter income was -32,240 K.
